Combination therapy for proliferative diseases

• US 10,953,004 B2
• Filed: 03/14/2017
• Issued: 03/23/2021
• Est. Priority Date: 03/14/2016
• Status: Active Grant

• Current Assignee: Avexxin AS
• Original Assignee: Avexxin AS
• Inventors: Johansen, Berit, Feuerherm, Astrid Jullumstro
• Primary Examiner(s): Ricci, Craig D
• Assistant Examiner(s): Coppins, Janet L.
• Application Number:
  US16/084,845
• Publication Number:
  US 20190076423A1
• Time in Patent Office: 1,470 Days
• Field of Search: 514293
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/121 acyclic
• CPC Class Codes: A61K 31/4745 condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61P 35/00 Antineoplastic agents

Abstract

A combination product comprising: (A) a compound of formula (I) R-L-CO—X (I) wherein R is a C_10-24 unsaturated hydrocarbon group optionally interrupted by one or more heteroatoms or groups of heteroatoms selected from S, O, N, SO, SO₂, said hydrocarbon group comprising at least 4 non-conjugated double bonds; L is a linking group forming a bridge of 1 to 5 atoms between the R group and the carbonyl CO wherein L comprises at least one heteroatom in the backbone of the linking group; and X is an electron withdrawing group; or a salt thereof; and (B) a compound of formula (X) where R₁ is phenyl wherein said phenyl is substituted by lower alkyl unsubstituted or substituted by cyano; R₃ is lower alkyl, such as methyl; and R₄ is quinolinyl unsubstituted or substituted by halogen; or a tautomer thereof, or a pharmaceutically acceptable salt, or a hydrate or solvate thereof.

Claims

1. A combination product comprising:

(A) Compound A or Compound B represented by one of the formulas below;

4. The combination product of claim 1, wherein the combination product is a fixed combination or non-fixed combination.

5. The combination product of claim 1, wherein the pharmaceutically acceptable salt of Compound BEZ235 is a 4-toluenesulfonic acid salt thereof.

2. A pharmaceutical composition comprising:

(A) Compound A or Compound B represented by one of the formulas below;

3. The pharmaceutical composition of claim 2 wherein the pharmaceutical composition is a fixed combination or non-fixed combination.

6. The pharmaceutical composition of claim 2, wherein the pharmaceutically acceptable salt of Compound BEZ235 is a 4-toluenesulfonic acid salt thereof.